POP MART(HK:09992) Guoyuan Securities·2025-08-27 04:11Investment Rating - The industry maintains a "Recommended" rating, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [6][32]. Core Insights - The report highlights a significant performance increase in the retail, social services, and beauty care sectors, with respective weekly gains of +4.55%, +4.55%, and +5.35%, outperforming the Shanghai Composite Index [2][13]. - Key companies in the beauty care sector reported mixed results, with some showing declines in revenue while others experienced growth, indicating a varied recovery across the industry [3][23][28]. - The IP derivatives segment, particularly Bubble Mart, demonstrated exceptional growth with a 204.4% increase in revenue year-on-year, showcasing strong market demand for collectible products [25][26]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 8th, 9th, and 5th respectively among 31 primary industries during the week of August 18-22, 2025, with notable increases in sub-sectors like internet e-commerce, education, and cosmetics [2][13][15]. Key Industry Data and News - Beauty Care: Estee Lauder reported a net sales decline of 8% for the fiscal year 2025, with a notable recovery in the Chinese market, achieving net sales of $2.741 billion [23]. - Travel Chain: Xiangyuan Culture achieved a revenue increase of 35.41% in H1 2025, indicating a strong recovery in tourism [4][28]. - IP Derivatives: Bubble Mart's revenue reached 13.88 billion yuan in H1 2025, a 204.4% increase, with significant contributions from various regions [25][26]. Company Announcements - Lao Pu Gold reported a revenue of 12.354 billion yuan in H1 2025, a 251.0% increase, with a net profit growth of 285.8% [27]. - Shanghai Jahwa achieved a revenue of 3.478 billion yuan, growing by 4.75%, with a net profit increase of 11.66% [30]. - Marubi Biological reported a revenue of 1.769 billion yuan, a 30.83% increase, with a net profit growth of 5.21% [30]. Investment Recommendations - The report suggests focusing on companies such as Shangmei, Juzi Biological, Marubi Biological, Runben, Proya, Chaohongji, Buluko, and Furida as potential investment targets within the recommended sectors [6][32].